NEW YORK (GenomeWeb) – Fluidigm today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price of $6.75 per share, for aggregate gross proceeds of about $55 million.
In addition, Fluidigm has granted underwriters of the offering a 30-day option to purchase up to 1,222,500 additional shares of common stock at the public offering price.
The South San Francisco, California-based life science research tools firm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures, and continued R&D with respect to products and technologies.
The offering is pursuant to a shelf registration filed with the US Securities and Exchange Commission on March 8, 2017, amended on April 28, 2017, and declared effective by the SEC on May 2, 2017.
Fluidigm said that the offering is expected to close on or about Dec. 14, subject to customary closing condition.